THE AMERICAN SOCIETY OF GENE & CELL THERAPY
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$27,046,811
Investments
88%
Cash & Equivalents
6%
Receivables (Non-Related)
2%
Prepaid Expenses
2%
Other Assets
2%
Property, Plant, & Equipment (net)
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$6,736,956
Deferred Revenue
87%
Payables & Accruals
7%
Other Liabilities
6%
Grants Payable
0%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$1,936,124
$1,495,276
-23%
Receivables (Non-Related)
$616,149
$588,423
-4%
Related-Party Receivables
-
-
-
Inventories
-
-
-
Prepaid Expenses
$456,617
$522,852
+15%
Investments
$20,155,555
$23,855,045
+18%
Property, Plant, & Equipment (net)
$99,116
$85,447
-14%
Other Assets
$546,817
$499,768
-9%
Total Assets
$23,810,378
$27,046,811
+14%
Liabilities
2023
2024
Change
Payables & Accruals
$420,123
$484,822
+15%
Grants Payable
-
-
-
Deferred Revenue
$5,534,184
$5,873,414
+6%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
$643,077
$378,720
-41%
Total Liabilities
$6,597,384
$6,736,956
+2%
Net assets
2023
2024
Change
Restricted Net Assets
$991,611
$637,389
-36%
Unrestricted Net Assets
$16,221,383
$19,672,466
+21%
Net assets
2023
2024
Change
Net assets
+$17,212,994
+$20,309,855
+18%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)